Pfizer, Albert Bourla
Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year. | For ...
A three-judge panel scrapped its own decision upholding dismissal of a racial discrimination lawsuit against Pfizer by anti-woke medical advocacy group Do No Harm on behalf of members – white and ...
A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...
Pfizer Inc.’s dispute with activist firm Starboard Value LP isn’t “an aggressive situation,” Chief Executive Officer Albert Bourla said, months after the feared investor disclosed a stake in the ...
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...
Leading biopharmaceutical company Pfizer has unveiled Cibinqo and Staquis, two innovative therapies designed to address eczema across its varying stages, now available in Malaysia. The announcement, ...
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...
CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback